pharmaceutical industry

Health By Meghana Keshavan

Tasty and easy to take, a new ADHD drug alarms some psychiatrists

Pharmalot By Ed Silverman

Vermont poised to become first state to require pharma to justify pricing

Pharmalot By Ed Silverman

FDA again delays rule to allow generic drug makers to change labels

Business By Meghana Keshavan

Drug makers struggle to revive interest in anti-obesity pills once seen as surefire hits

Business By Damian Garde

Pulitzer Prize-winning doctor wades into biotech with cancer startup

Business By Damian Garde

4 people shaping Kendall Square’s future

Business By Damian Garde

Get to know Kendall Square, biotech’s booming epicenter of big risks and bright minds

Business By Damian Garde

No stranger to gambling, this biotech CEO is going all-in on a first drug approval

In the Lab By Ike Swetlitz

How ketamine eases depression — and why that matters for the drug industry

The Pharmalot View By Ed Silverman

Who should pay for disposing unused drugs? Pharma says: not us

Business By Rebecca Robbins

Forced to discount pricey hepatitis C drugs, Gilead misses sales target

Pharmalot By Ed Silverman

Pharma pushed by investment funds to pay for drug take-back programs

Business By Damian Garde

How an open-science advocate aims to shake up pharma

Business By Damian Garde

Lessons from the biotech trenches: How to jump from corner office to startup

First Opinion By Patrick Skerrett

Pharma and biotech companies: Don’t just merge, innovate

Politics By Rebecca Robbins

At big drug ad conference, industry urged to fight ‘crescendo of criticism’

Business By Andrew Joseph

Chinese biopharma companies set down roots in Boston area

The Pharmalot View By Ed Silverman

This nonprofit is playing a valuable role in framing the drug price discussion

Politics By David Nather

The one drug pricing idea Hillary Clinton and PhRMA can agree on

In the Lab By Eric Boodman

In high-tech hub, this scientist hunts for cures in the greenhouse

The Pharmalot View By Ed Silverman

What Valeant’s fall from grace can teach the drug industry